📊 PGNY Key Takeaways
Is Progyny, Inc. (PGNY) a Good Investment?
Progyny demonstrates strong financial health with a pristine balance sheet, excellent liquidity, and robust free cash flow generation. However, net income is flat YoY despite 10.4% revenue growth, signaling concerning margin compression and deteriorating operating leverage that requires immediate management attention.
Progyny, Inc. Key Strengths (PGNY)
- Fortress balance sheet: $131.6M cash, zero debt, 2.13x current ratio provides substantial financial flexibility
- Strong free cash flow generation: $39.6M FCF (12.1% margin) demonstrates efficient cash conversion and low capital intensity
- Conservative capital structure: Asset-light business model with minimal CapEx ($6.3M) and no financial leverage
PGNY Stock Risks: Progyny, Inc. Investment Risks
- Deteriorating profitability: Net income flat YoY (0% growth) despite 10.4% revenue growth indicates operating expenses outpacing top-line growth
- Poor capital efficiency: 5.5% ROE and 3.5% ROA are below industry standards, showing ineffective deployment of shareholder capital
- Margin compression concerns: 7.4% net margin and 25.3% gross margin are below typical healthcare services benchmarks
Key Metrics to Watch
- Operating margin and gross margin trends - critical to determine if compression is structural or temporary
- Net income growth rate relative to revenue growth - must demonstrate improving operating leverage
- Return on equity trajectory - essential for assessing long-term shareholder value creation potential
Progyny, Inc. (PGNY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.13x current ratio provides a solid financial cushion.
PGNY Profit Margin, ROE & Profitability Analysis
PGNY vs Services Sector: How Progyny, Inc. Compares
How Progyny, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Progyny, Inc. Stock Overvalued? PGNY Valuation Analysis 2026
Based on fundamental analysis, Progyny, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Progyny, Inc. Balance Sheet: PGNY Debt, Cash & Liquidity
PGNY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Progyny, Inc.'s revenue has grown significantly by 64% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.62 reflects profitable operations.
PGNY Revenue Growth, EPS Growth & YoY Performance
PGNY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $324.0M | $15.1M | $0.17 |
| Q3 2025 | $286.6M | $10.4M | $0.11 |
| Q2 2025 | $304.1M | $16.5M | $0.17 |
| Q1 2025 | $278.1M | $15.1M | $0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Progyny, Inc. Dividends, Buybacks & Capital Allocation
PGNY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Progyny, Inc. (CIK: 0001551306)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PGNY
What is the AI rating for PGNY?
Progyny, Inc. (PGNY) has an AI grade of B with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PGNY's key strengths?
Claude: Fortress balance sheet: $131.6M cash, zero debt, 2.13x current ratio provides substantial financial flexibility. Strong free cash flow generation: $39.6M FCF (12.1% margin) demonstrates efficient cash conversion and low capital intensity.
What are the risks of investing in PGNY?
Claude: Deteriorating profitability: Net income flat YoY (0% growth) despite 10.4% revenue growth indicates operating expenses outpacing top-line growth. Poor capital efficiency: 5.5% ROE and 3.5% ROA are below industry standards, showing ineffective deployment of shareholder capital.
What is PGNY's revenue and growth?
Progyny, Inc. reported revenue of $328.5M.
Does PGNY pay dividends?
Progyny, Inc. does not currently pay dividends.
Where can I find PGNY SEC filings?
Official SEC filings for Progyny, Inc. (CIK: 0001551306) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PGNY's EPS?
Progyny, Inc. has a diluted EPS of $0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PGNY's fundamental grade?
Based on our AI fundamental analysis in May 2026, Progyny, Inc. has a B grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PGNY stock overvalued or undervalued?
Valuation metrics for PGNY: ROE of 5.5% (sector avg: 16%), net margin of 7.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is PGNY's AI grade for 2026?
Our dual AI analysis gives Progyny, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PGNY's free cash flow?
Progyny, Inc.'s operating cash flow is $45.9M, with capital expenditures of $6.3M. FCF margin is 12.1%.
How does PGNY compare to other Services stocks?
Vs Services sector averages: Net margin 7.4% (avg: 10%), ROE 5.5% (avg: 16%), current ratio 2.13 (avg: 1.5).